Table 2.
PICU therapeutic interventions between survivors and non-survivors
| Survivors (n = 56) | Non-survivors (n = 11) | Total (n = 67) | p value | |
|---|---|---|---|---|
| Median of PICU stay, days | 11 (7.75, 18) | 15 (11, 19.5) | 11 (8, 18) | 0.861 |
| Median of hospital stay, days | 22.5 (16, 34.25) | 17 (16, 23.5) | 22 (16, 31) | 0.124 |
| Co-morbidity, n (%) | ||||
| ARDS | 27 (48.21%) | 9 (81.82%) | 36 (53.73%) | 0.041 |
| Liver dysfunction | 21 (31.34%) | 10 (90.9%) | 31 (46.27%) | 0.001 |
| AKI | 4 (7.14%) | 5 (45.45%) | 9 (13.43%) | 0.001 |
| shock | 42 (75%) | 10 (90.9%) | 52 (77.61%) | 0.247 |
| GI dysfunction | 31 (55.36%) | 11 (100%) | 42 (62.69%) | 0.005 |
| PICU and hospital therapies, n (%) | ||||
| Invasive Mechanical ventilation | 51 (91.07%) | 11 (100%) | 62 (92.54%) | 0.303 |
| CRRT/RRT | 11 (19.64%) | 8 (72.73%) | 19 (28.36%) | <0.001 |
| ECMO | 6 (10.71%) | 3 (37.5%) | 9 (13.43%) | 0.141 |
| Prone positioning, n (%) | 15 (26.79%) | 4 (36.36%) | 19 (28.36%) | 0.519 |
| Neuromuscular blockade, n (%) | 22 (39.29%) | 8 (72.73%) | 30 (44.78%) | 0.041 |
| Vasoactive use | 48 (85.71%) | 10 (90.9%) | 58 (86.57%) | 0.644 |
| diuretics use | 43 (76.79%) | 8 (72.73%) | 51 (76.12%) | 0.773 |
| Steroids use | 55 (98.21%) | 11 (100%) | 66 (98.51%) | 0.655 |
| IV immunoglobulin | 50 (89.29%) | 10 (90.9%) | 60 (89.55%) | 0.872 |
| Parenteral nutrition | 12 (21.43%) | 10 (90.9%) | 22 (32.84%) | <0.001 |
| Packed red blood cell perfusion | 28 (50%) | 10 (90.9%) | 38 (56.72%) | 0.012 |
| Nosocomial infenctiona, n (%) | 15 (26.79%) | 7 (63.64%) | 22 (32.84%) | 0.017 |
| bacterial | 15 (26.79%) | 7 (63.64%) | 22 (32.84%) | 0.043 |
| fungal | 4 (7.14%) | 1 (9.09%) | 5 (7.46%) | 0.687 |
aparts of patients complicated with bacteria, mycoplasma pneumoniae or fungi in nosocomial infection or co-infection